Clovis Oncology, Inc. (NASDAQ:CLVS) Files An 8-K Entry into a Material Definitive Agreement

Clovis Oncology, Inc. (NASDAQ:CLVS) Files An 8-K Entry into a Material Definitive Agreement

Story continues below

Clovis Oncology, Inc. Exhibit
EX-10.1 2 d723951dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 FINANCING AGREEMENT dated as of May 1,…
To view the full exhibit click here

About Clovis Oncology, Inc. (NASDAQ:CLVS)

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).

An ad to help with our costs